Biden Administration seeks to put its stamp on a new phase of the US government’s collaboration with the pharma industry against COVID-19.
The pharma industry got a star turn at the White House 10 March as Johnson & Johnson CEO Alex Gorsky and Merck & Co., Inc. CEO Ken Frazier joined US President Biden in celebrating the “historic” manufacturing collaboration between the companies aimed at accelerating the production of J&J’s COVID-19 vaccine.
“Today we’re seeing two health companies, competitors, each with over 130 years of experience, coming together to write a more hopeful chapter in our battle with COVID-19,” Biden said
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An ‘historic economic prosperity deal’ does not include the sector.
